products and the proposed combination microbicide
will provide a three layer barrier to HIV infection. Initially, the product
will inactivate HIV and HIV-infected cells in the semen upon introduction
to the vagina. Secondly, two separate products in the combination will
prevent the initial attachment and subsequent entry of virus into the
vaginal target cells, preventing infection. Finally, the third and most
potent activity of the product will prevent the critical action of the
virus-encoded reverse transcriptase inside the cell. Key features of the
development program include the formulation of the product for delivery as
gels or intravaginal rings, pharmacokinetic and pharmacodynamic evaluations
to demonstrate the feasibility of the formulated product for use,
acceptability studies to assure that the final product will be used by the
women it is intended to protect, and the IND-directed preclinical and
clinical activities required to initiate FDA-approved human clinical trials
for the unique final product.
ImQuest CEO, Joseph McGuirl states, "We are highly honored that the NIH
has seen fit to fund this important microbicide development program and we
look forward to working closely with our team of academic collaborators and
the NIH to successfully achieve our goals."
ImQuest Life Sciences, a privately held U.S. company located in
Frederick, Maryland specializes in early stage drug development of novel
compounds for the treatment of infectious disease and cancer. ImQuest
BioSciences, also located in Frederick, Maryland, is a leading provider of
anti-infective therapeutic and microbicide development services to the
biotechnology and pharmaceutical industry.
For further information regarding this press release please contact:
Robert W. Buckheit, Jr., Ph.D.
Executive Vice President and Chief Scientific Officer
ImQuest Life Sciences, Inc.
email@example.comPage: 1 2 3 Related biology technology :1
. ImQuest Awarded SBIR Grant to Define the Mechanism of Action of Their Lead Anti-HIV Therapeutic Compound IQP-04102
. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis3
. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market4
. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy5
. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children6
. IsoTis Receives FDA Clearance for Accell Family of Products7
. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.8
. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II9
. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma10
. XTL Receives Staff Letter From NASDAQ11
. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market